

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ELI LILLY AND COMPANY,
Petitioner

v.

TEVA PHARMACEUTICALS INTERNATIONAL GMBH,
Patent Owner

Case IPR2018-01427
Patent 8,597,649 B2

**TEVA PHARMACEUTICALS INTERNATIONAL
GMBH'S REPLY IN SUPPORT OF THE MOTION TO EXCLUDE**

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

I.	Exhibit 1287 lacks foundation and should be excluded.....	1
II.	Lilly relies upon inadmissible deposition testimony.....	4
III.	Multiple exhibits are irrelevant, prejudicial, and lack probative value.....	5
IV.	Conclusion.....	5

The Board should grant Teva's Motion to Exclude Evidence ("Motion") because Lilly's Opposition to the Motion ("Opposition") misrepresents the law and offers irrelevant arguments that fail to rebut Teva's showing that the challenged evidence is inadmissible, as explained below.

I. Exhibit 1287 lacks foundation and should be excluded.

Teva's Motion addresses and identifies several reasons why Exhibit 1287 is inadmissible in these proceedings and should be excluded under FRE 901. Motion, 2-7. Significantly, the evidentiary flaws associated with authentication of EX1287 remain unrebutted. *Id.* Lilly's Opposition does not address the lack of evidence regarding the cataloguing and shelving practices of the Cambridge University Library ("CUL"), the confusion and inconsistency regarding EX1287's purported dates of availability and cataloguing, Lilly's provision of inadmissible hearsay evidence as supplemental evidence (Ms. Clarke's email), or the fact that even her hearsay statement casts doubt on the authenticity of EX1287. None of Lilly's arguments in reply remedy the foundational defects for EX1287.

First, Lilly argues that because Teva refers to EX1287 as a "dissertation by Dr. Tan," "Teva does not dispute that Exhibit 1287 is Dr. Tan's doctoral thesis." Opposition, 1 (citing Teva's Motion to Strike, Paper 43, 2). Reference to the purported identity of an exhibit, however, does not indicate acceptance of that identity. *Id.* As is apparent from Teva's Motion, Teva has consistently objected to

and maintained that Lilly has not authenticated EX1287 as Dr. Tan's thesis.

Motion, 3; EX1303, 176:2-18; Paper 39, 2.

Next, Lilly casts Teva's arguments regarding EX1287 as one of public accessibility, "not properly raised in a motion to exclude." Opposition, 2. But Lilly itself linked EX1287's foundation to "public availability" after Teva objected. EX1307, ¶19. Authentication necessarily requires producing evidence sufficient to support a finding that the item (a thesis) is what the proponent claims it is—a document, which in Lilly's words, purports to be evidence from "actual researchers in the field before November 2005." FRE 901(a); Opposition, 2. Teva cited to cases relating to public availability because those cases identify the evidence that is necessary to establish the origin and public availability of EX1287 before 2005. Opposition, 2. As explained in Teva's Motion, the absence of such evidence undermines Lilly's efforts to authenticate EX1287 under FRE 901—Lilly's Reply provides nothing to supplement that lack of evidence.

Faced with a gap in its authentication evidence, Lilly argues that it used EX1287 for purposes that don't require prior art status. *Id.*, 2-3. Lilly's assertion is irrelevant—a document must be authenticated regardless of Lilly's intended use. Further, Lilly supports its flawed assertion by a selective and misleading quotation from a single non-precedential decision. *Id.*, 2 (citing *Chi. Mercantile Exch., Inc. v. 5th Mkt., Inc.*, CBM2014-00114, Paper 35 (PTAB Aug. 18, 2015) ("CME")). The

CME panel acknowledged that “a motion to exclude is not the proper vehicle to challenge the sufficiency of the evidence used to demonstrate that [an exhibit] qualifies as a prior art printed publication within the meaning of § 102(b).” *Id.*, 52. However, Lilly neglected to disclose that the panel then held that “addressing the admissibility of evidence, e.g., authenticity or hearsay, underlying the factual determinations of whether [the exhibit] is a prior art printed publication ***may be the subject of a motion to exclude.***” *Id.* The *CME* panel properly analyzed whether there was “credible or sufficient evidence as to where [the exhibit in question was] obtained” and when it “was made available publicly.” *Id.*, 53. Applying just such an analysis—as performed in Teva’s Motion—shows that EX1287 lacks sufficient foundation.

Finally, Lilly’s argument that EX1287 is a “self-authenticating ancient document” also lacks merit. Opposition, 1-2. Lilly offers a conclusory assertion sans support that a Cambridge thesis purportedly from 1994 would qualify as an ancient document. *Id.* Lilly’s assertion suffers from a critical flaw: Lilly has not presented sufficient evidence to establish the baseline facts regarding EX1287’s identity or date of publication. Nor has Lilly established that such date of publication would be considered “ancient.” Therefore, Lilly has not adequately authenticated EX1287 or established it as a self-authenticating document. The Board should exclude EX1287 from this record.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.